Viridian Therapeutics, Inc. (VRDN)
19.56
+1.18
(+6.42%)
USD |
NASDAQ |
Oct 15, 16:00
19.54
-0.02
(-0.10%)
After-Hours: 20:00
Viridian Therapeutics Research and Development Expense (Quarterly) : 71.46M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.46M |
| March 31, 2026 | 77.51M |
| December 31, 2025 | 89.09M |
| September 30, 2025 | 86.15M |
| June 30, 2025 | 86.51M |
| March 31, 2025 | 76.72M |
| December 31, 2024 | 71.84M |
| September 30, 2024 | 69.03M |
| June 30, 2024 | 55.95M |
| March 31, 2024 | 40.80M |
| December 31, 2023 | 38.41M |
| September 30, 2023 | 30.25M |
| June 30, 2023 | 39.95M |
| March 31, 2023 | 50.64M |
| December 31, 2022 | 39.22M |
| September 30, 2022 | 22.12M |
| June 30, 2022 | 21.66M |
| March 31, 2022 | 17.71M |
| December 31, 2021 | 22.36M |
| September 30, 2021 | 8.091M |
| June 30, 2021 | 12.54M |
| March 31, 2021 | 13.77M |
| December 31, 2020 | 15.20M |
| September 30, 2020 | 2.911M |
| June 30, 2020 | 3.647M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.96M |
| December 31, 2019 | 8.344M |
| September 30, 2019 | 8.956M |
| June 30, 2019 | 8.528M |
| March 31, 2019 | 8.751M |
| December 31, 2018 | 8.234M |
| September 30, 2018 | 7.399M |
| June 30, 2018 | 8.375M |
| March 31, 2018 | 6.413M |
| December 31, 2017 | 4.998M |
| September 30, 2017 | 5.018M |
| June 30, 2017 | 5.487M |
| March 31, 2017 | 4.12M |
| December 31, 2016 | 3.906M |
| September 30, 2016 | 2.965M |
| June 30, 2016 | 0.334M |
| March 31, 2016 | 0.307M |
| December 31, 2015 | 0.456M |
| September 30, 2015 | 0.253M |
| June 30, 2015 | 0.194M |
| March 31, 2015 | 0.10M |
| December 31, 2014 | 0.1447M |
| September 30, 2014 | 0.0762M |
| June 30, 2014 | 0.009M |
| December 31, 2013 | 0.0182M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 993.80M |
| TG Therapeutics, Inc. | 95.34M |
| Travere Therapeutics, Inc. | 60.28M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |